Please ensure Javascript is enabled for purposes of website accessibility

Why Heron Therapeutics' Stock Sank Today

By George Budwell – Feb 8, 2016 at 12:45PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares continue to churn lower along with the bulk of the entire biotech industry.

What: Shares of the biotech company Heron Therapeutics (HRTX -3.02%) sank by as much as 15.8% today on greater-than-normal volume for the stock. The good news is that this latest downturn wasn't triggered by a negative catalyst; rather, the stock appears to be caught in the broader sell-off occurring across the entire biotech industry at the moment. 

So what: Heron's shares are now down a staggering 59% from their 52-week highs, according to S&P Global Market Intelligence:

HRTX Chart

HRTX data by YCharts.

Even so, Heron has actually made major strides toward building out a profitable product portfolio over the past year -- headlined by the experimental chemotherapy-induced nausea drug, Sustol, that is currently under regulatory review with the U.S. Food and Drug Administration.

Now what: Last month, the FDA notified Heron that it had not yet completed its review of Sustol, pushing the drug's regulatory decision into late February. Unfortunately, this regulatory delay has only served to accelerate the stock's move lower, with Heron's shares shedding a hefty 25% of their value since Jan. 15 when the announcement hit the Street. 

On the flip side, most of the analysts covering this stock have remained extremely bullish, despite the FDA's tardiness on Sustol's regulatory decision. For example, Heron's average 12-month price target presently sits at $50.63, implying that shares could essentially triple from current levels. 

While that's certainly an impressive amount of upside potential, I'm personally willing to wait on the FDA's decision before buying shares. After all, this keystone event isn't a slam dunk by any means, as evidenced by Sustol's prior regulatory reviews .  

George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
HRTX
$3.86 (-3.02%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.